Long-acting β-adrenoceptor agonists in the management of COPD: Focus on indacaterol

International Journal of COPD

Volumn 6, Issue 1, 2011, Pages 237-243

  Beier, Jutta ^a   Beeh, Kai M ^a  

^a Institut fur Atemwegsforschung INSAF   (Germany)

Author keywords

Bronchodilators; COPD; Formoterol; Indacaterol; Pharmacology; Salmeterol; Therapy; Tiotropium

Indexed keywords

BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BRONCHODILATING AGENT; CORTICOSTEROID; FORMOTEROL; INDACATEROL; IPRATROPIUM BROMIDE; LONG ACTING DRUG; PLACEBO; SALMETEROL; SHORT ACTING DRUG; THEOPHYLLINE; TIOTROPIUM BROMIDE; 5 (2 (5,6 DIETHYLINDAN 2 YLAMINO) 1 HYDROXYETHYL) 8 HYDROXY 1H QUINOLIN 2 ONE; 5-(2-(5,6-DIETHYLINDAN-2-YLAMINO)-1-HYDROXYETHYL)-8-HYDROXY-1H-QUINOLIN-2-ONE; INDAN DERIVATIVE; QUINOLONE DERIVATIVE;

ASTHMA; BLOOD PRESSURE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL EFFECTIVENESS; COUGHING; DISEASE CONTROL; DISEASE SEVERITY; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE REDUCTION; DRUG EFFECT; DRUG EFFICACY; DRUG ELIMINATION; DRUG FATALITY; DRUG HALF LIFE; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; DYSPNEA; ELECTROCARDIOGRAM; FORCED EXPIRATORY VOLUME; GLUCOSE BLOOD LEVEL; HEADACHE; HEART ARRHYTHMIA; HEART PALPITATION; HUMAN; HYPOKALEMIA; INSPIRATORY CAPACITY; MAINTENANCE THERAPY; NONHUMAN; OUTCOME ASSESSMENT; POTASSIUM BLOOD LEVEL; PRIMARY HEALTH CARE; PULSE RATE; QT INTERVAL; QT PROLONGATION; QUALITY OF LIFE; RECOMMENDED DRUG DOSE; REVIEW; SIDE EFFECT; SINGLE DRUG DOSE; TACHYCARDIA; TIME TO MAXIMUM PLASMA CONCENTRATION; TREATMENT DURATION; TREATMENT PLANNING; TREMOR; DRUG ADMINISTRATION; EVIDENCE BASED MEDICINE; LUNG; PATHOPHYSIOLOGY; TREATMENT OUTCOME;

ADRENERGIC BETA-2 RECEPTOR AGONISTS; BRONCHODILATOR AGENTS; DRUG ADMINISTRATION SCHEDULE; EVIDENCE-BASED MEDICINE; HUMANS; INDANS; LUNG; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE; QUINOLONES; TREATMENT OUTCOME;

EID: 79960454642     PISSN: 11769106     EISSN: 11782005     Source Type: Journal    
DOI: 10.2147/COPD.S7371     Document Type: Review

References (58)

1. Global Initiative for Chronic Obstructive Lung Disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease: 2008 update. http://www.goldcopd.com/. Accessed March 21, 2011.
2. Sin DD, MacAlister FA, Man SFP, Anthonisen NR. Contemporary management of chronic obstructive pulmonary disease. JAMA. 2003; 290:2301-2312.
3. Tashkin D P, Cooper CB. The role of long-acting bronchodilators in the management of stable COPD. Chest. 2004;125:249-259.
4. Decramer M, Celli B, Kesten S, et al. Effect of tiotropium on outcomes in patients with moderate chronic obstructive pulmonary disease (UPLIFT): a prespecified subgroup analysis of a randomised controlled trial. Lancet. 2009;374:1171-1178.
5. Celli B, Decramer M, Kesten S, et al. Mortality in the 4-year trial of tiotropium (UPLIFT) in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2009;180:948-955.
6. Bourbeau J, Bartlett SJ. Patient adherence in COPD. Thorax. 2008;63: 831-838.
7. Vestbo J, Anderson JA, Calverley PMA, et al. Adherence to inhaled therapy, mortality and hospital admission in COPD. Thorax. 2009;64: 939-943.
8. Cazzola M, Santangelo G, Piccolo A, et al. Effect of salmeterol and formoterol in patients with chronic obstructive pulmonary disease. Pulm Pharmacol. 1994;7:103-107.
9. Cazzola M, Matera MG, Santangelo G, et al. Salmeterol and formoterol in partially reversible severe chronic obstructive pulmonary disease: a dose-response study. Respir Med. 1995;89:357-362.
10. Dahl R, Greefhorst LA, Nowak D, et al. Inhaled formoterol dry powder versus ipratropium bromide in chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;164:778-784.
11. Matera MG, Cazzola M, Vinciguerra A, et al. A comparison of the bronchodilating effects of salmeterol, salbutamol and ipratropium bromide in patients with chronic obstructive pulmonary disease. Pulm Pharmacol. 1995;8:267-271.
12. Mahler DA, Donohue JF, Barbee RA, et al. Efficacy of salmeterol xinafoate in the treatment of COPD. Chest. 1999;115:957-965.
13. Rennard SI, Anderson W, ZuWallack R, et al. Use of a long-acting inhaled beta2-adrenergic agonist, salmeterol xinafoate, in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2001;163:1087-1092.
14. Cote C, Pearle JL, Sharafkhaneh A, Spangenthal S. Faster onset of action of formoterol versus salmeterol in patients with chronic obstructive pulmonary disease: a multicenter, randomized study. Pulm Pharmacol Ther. 2009;22:44.
15. Bouros D, Kottakis J, Le Gros V, et al. Effects of formoterol and salmeterol on resting inspiratory capacity in COPD patients with poor FEV(1) reversibility. Curr Med Res Op. 2004;20:581-586.
16. Celik G, Kayacan O, Beder S, Durmaz G. Formoterol and salmeterol in partially reversible chronic obstructive pulmonary disease: a crossover, placebo-controlled comparison of onset and duration of action. Respiration. 1999;66:434-439.
17. Szafranski W, Cukier A, Ramirez A, et al. Efficacy and safety of budes-onide/formoterol in the management of chronic obstructive pulmonary disease. Eur Respir J. 2003;21:74-81.
18. Calverley PMA, Boonsawat W, Cseke Z, et al. Maintenance therapy with budesonide and formoterol in chronic obstructive pulmonary disease. Eur Respir J. 2003;22:912-919.
19. Calverley PMA, Anderson JA, Celli BR, et al. Salmeterol and futica-sone propionate and survival in chronic obstructive pulmonary disease. N Engl J Med. 2007;356:775-789.
20. Calverley PMA, Pauwels R, Vestbo J, et al. Combined salmeterol and futicasone in the treatment of chronic obstructive pulmonary disease: a randomised controlled trial. Lancet. 2003;361:449-456.
21. Brusasco V, Hodder R, Miravitlles M, et al. Health outcomes following treatment for six months with once daily tiotropium compared with twice daily salmeterol in patients with COPD. Thorax. 2003;58:399-404.
22. Donohue J F, Van Noord JA, Langley SJ, et al. Superior bronchodilation of once daily tiotropium compared to twice daily salmeterol in patients with COPD. Eur Respir J. 2001;18:26s.
23. Briggs JDD, Covelli H, Lapidus R, et al. Improved daytime spirometric efficacy of tiotropium compared with salmeterol in patients with COPD. Pulm Pharmacol Ther. 2005;18:397-404.
24. Richter K, Stenglein S, Mocke M, et al. Onset and duration of action of formoterol and tiotropium in patients with moderate to severe COPD. Respiration. 2006;73:414-419.
25. Vogelmeier C, Kardos P, Harar Si, et al. Formoterol mono- and combination therapy with tiotropium in patients with COPD: a 6-month study. Respir Med. 2008;102:1511-1520.
26. Beeh KM, Hederer B, Glaab T, et al. Study design considerations in a large COPD trial comparing effects of tiotropium with salmeterol on exacerbations. Int J COPD. 2009;4:119-124.
27. Naline E, Triflieff A, Fairhurst RA, et al. Effect of indacaterol, a novel long-acting beta2-agonist, on isolated human bronchi. Eur Respir J. 2007;29:575-281.
28. Battram C, Charlton SJ, Cuenoud B, et al. In vitro and in vivo pharmacological characterization of 5-[(R)-2-(5,6-diethyl-indan-2-ylamino)-1-hydroxy-ethyl]-8-hydroxy-1H-quinolin-2-one (indacaterol), a novel inhaled beta(2) adrenoceptor agonist with a 24-h duration of action. J Pharmacol Exp Ther. 2006;317:762-770.
29. Sturton RG, Triflieff A, Nicholson AG, Barnes PJ. Pharmacological characterization of indacaterol, a novel once daily inhaled beta2 adrenoceptor agonist, on small airways in human and rat precision cut slices. J Pharmacol Exp Ther. 2008;324:270-275.
30. Lombardi D, Cuenoud B, Kraemer SD. Lipid membrane interactions of indacaterol and salmeterol: do they influence their pharmacology properties? Eur J Pharm Sci. 2009;38:533-547.
31. Rosethorne E, Turner R, Fairhurst R, Charlton S. Efficacy is a contributing factor to the clinical onset of bronchodilation of inhaled beta(2)-adrenoceptor agonists. Naunyn Schmiedebergs Arch Pharmacol. 2010; 382:255-263.
32. Tarral A, Fauchoux N, Knight H, et al. Safety and tolerability of multiple-dose indacaterol, a novel.2-agonist, in patients with mild asthma. Eur Respir J. 2005;26(Suppl 49):253s.
33. Duvauchelle T, Elharrar B, Knight H, et al. Single-dose indacaterol, a novel 24-hour.2-agonist, is well tolerated in patients with mild asthma. Eur Respir J. 2005;26(Suppl 49):253s.
34. Perry S, Woessner R, Kaiser G, et al. Pharmakokinetics of indacaterol after single and multiple inhaled doses. Am J Respir Crit Care Med. 2010;181:A4420.
35. Rennard S, Bantje T, Centanni S, et al. A dose-ranging study of inda-caterol in obstructive airways disease, with a tiotropium comparison. Respir Med. 2008;102:1033-1044.
36. Beeh KM, Derom EY, Kanniess F, et al. Indacaterol, a novel once-daily 2-agonist, provides sustained 24-hour bronchodilator efficacy in asthma. Eur Respir J. 2007;29:871-878.
37. Beier J, Beeh KM, Pascoe S, et al. Bronchodilator effects of indacaterol and formoterol in patients with COPD. Pulm Pharmacol Ther. 2009; 22:492-496.
38. Chapman KR, Rennard SI, Dogra A, et al. Long-term safety and efficacy of indacaterol, a novel long-acting {beta}2-agonist, in subjects with COPD: a randomized, placebo-controlled study. Chest. Feb 24, 2011. [Epub ahead of print].
39. Kornmann O, Dahl R, Centanni S, et al. Once-daily indacaterol versus twice-daily salmeterol for COPD: a placebo-controlled comparison. Eur Respir J. 2011;37:273-279.
40. Feldman G, Siler T, Prasad N, et al. Efficacy and safety of indacaterol 150 μg once-daily in COPD: a double-blind, randomised, 12-week study. BMC Pulmonary Medicine. 2010;10:11.
41. LaForce C, Aumann J, de Teresa Parreno L, et al. Sustained 24-hour efficacy of once daily indacaterol (300 mcg) in patients with chronic obstructive pulmonary disease: a randomized, crossover study. Pulm Pharmacol Ther. 2011;24:162-168.
42. Korn S, Kerwin E, Atis S, et al. Indacaterol once-daily provides superior efficacy to salmeterol twice-daily in COPD: a 12-week study. Respir Med. 2011. In press, corrected proof.
43. Dahl R, Chung K F, Buhl R, et al. Efficacy of a new once-daily long-acting inhaled beta2-agonist indacaterol versus twice-daily formoterol in COPD. Thorax. 2010;65:473-479.
44. Donohue JF, Decramer M, Owen R, et al. Indacaterol provides significant bronchodilation in patients with chronic obstructive pulmonary disease irrespective of concomitant inhaled corticosteroid use. Am J Respir Crit Care Med. 2010;181:A4438.
45. Donohue JF, Fogarty C, Lotvall J, et al. Once-daily bronchodilators for chronic obstructive pulmonary disease: indacaterol versus tiotropium. Am J Respir Crit Care Med. 2010;182:155-162.
46. Vogelmeier C, Ramos-Barbon D, Jack D, et al. Indacaterol provides 24-hour bronchodilation in COPD: a placebo-controlled blinded comparison with tiotropium. Respiratory Research. 2010;11(1):135.
47. Dunn LJ, Buhl R, Lassen C, et al. Blinded 12-week comparison of once-daily indacaterol and tiotropium in COPD. Chest. 2010;138:719A.
48. Kleerup E, Williams J, Yegen U, et al. The effect of indacaterol once-daily on health-related quality of life, symptoms and rescue medication use in moderate-to-severe chronic obstructive pulmonary disease: pooled analysis of six month data. Am J Respir Crit Care Med. 2010;181: A4429.
49. Siler T, Williams J, Yegen U, et al. The effect of once-daily indacaterol on health-related quality of life, rescue medication use, and exacerbation rates in patients with moderate-to-severe COPD: a pooled analysis of three months of treatment. Am J Respir Crit Care Med. 2010;181: A4430.
50. Mahler DA, Buhl R, Owen R, et al. Indacaterol provides effective bronchodilation in patients with chronic obstructive pulmonary disease irrespective of patient age (,65 or.65 years). Am J Respir Crit Care Med. 2010;181:A4456.
51. Kleerup E, D'Urzo A, Owen R, et al. Once-daily indacaterol provides significant bronchodilation in chronic obstructive pulmonary disease patients irrespective of baseline reversibility. Am J Respir Crit Care Med. 2010;181:A4439.
52. Chuchalin A, Tsoi AN, Richter K, et al. Safety and tolerability of indacaterol in asthma: a randomized, placebo-controlled 28-day study. Respir Med. 2007;101:2065-2075.
53. Yang WH, Martinot JB, Pohunek P, et al. Tolerability of indacaterol, a novel once-daily 2-agonist, in patients with asthma: a randomized, placebo-controlled, 28-day safety study. Ann Allergy Asthma Immunol. 2007;99:555-561.
54. Beier J, Chanez P, Martinot JB, et al. Safety, tolerability and efficacy of indacaterol, a novel once-daily 2-agonist, in patients with COPD: a 28-day randomised, placebo-controlled clinical trial. Pulm Pharmacol Ther. 2007;20:740-749.
55. Khindri S, Sabo R, Harris S, et al. Cardiac safety of indacaterol - no clinical effect on QT interval in healthy subjects. Eur Respir J. 2009; 34(Suppl 53):P2031.
56. Pascoe S, Reynolds C, Pleskow W, et al. Safety, tolerability and pharma-cokinetics of single escalating doses of indacaterol, a once-daily beta2-agonist bronchodilator, in subjects with COPD. Int J Clin Pharmacol. 2011;49:153-161.
57. Worth H, Kleerup E, Iqbal A, et al. Safety and tolerability of indacaterol once-daily in COPD patients versus placebo and tiotropium: a 26-week study Eur Respir J. 2009;34(Suppl 53):P2030.
58. Worth H, Chung KF, Felser JM, et al. Cardio- and cerebrovascular safety of indacaterol vs formoterol, salmeterol, tiotropium and placebo in COPD. Respir Med. 2011;105:571-579.